1129 related articles for article (PubMed ID: 8256501)
1. GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3.
Livingston PO; Calves MJ; Helling F; Zollinger WD; Blake MS; Lowell GH
Vaccine; 1993 Sep; 11(12):1199-204. PubMed ID: 8256501
[TBL] [Abstract][Full Text] [Related]
2. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
Helling F; Shang A; Calves M; Zhang S; Ren S; Yu RK; Oettgen HF; Livingston PO
Cancer Res; 1994 Jan; 54(1):197-203. PubMed ID: 8261439
[TBL] [Abstract][Full Text] [Related]
3. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma.
Ritter G; Ritter-Boosfeld E; Adluri R; Calves M; Ren S; Yu RK; Oettgen HF; Old LJ; Livingston PO
Int J Cancer; 1995 Sep; 62(6):668-72. PubMed ID: 7558412
[TBL] [Abstract][Full Text] [Related]
5. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides.
Lowell GH; Ballou WR; Smith LF; Wirtz RA; Zollinger WD; Hockmeyer WT
Science; 1988 May; 240(4853):800-2. PubMed ID: 2452484
[TBL] [Abstract][Full Text] [Related]
6. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
[TBL] [Abstract][Full Text] [Related]
7. Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin.
Helling F; Livingston PO
Mol Chem Neuropathol; 1994; 21(2-3):299-309. PubMed ID: 8086040
[TBL] [Abstract][Full Text] [Related]
8. Specific serological response by active immunization with GD3-bearing liposomes.
Massó O; Aliño SF; Lejarreta M; Blasco F; Piulats J
J Pharmacol Exp Ther; 1996 Sep; 278(3):1114-20. PubMed ID: 8819493
[TBL] [Abstract][Full Text] [Related]
9. Immunopotentiating ability of neisserial major outer membrane proteins. Use as an adjuvant for poorly immunogenic substances and potential use in vaccines.
Wetzler LM
Ann N Y Acad Sci; 1994 Aug; 730():367-70. PubMed ID: 8080211
[No Abstract] [Full Text] [Related]
10. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
[TBL] [Abstract][Full Text] [Related]
11. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
Livingston PO; Calves MJ; Natoli EJ
J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
[TBL] [Abstract][Full Text] [Related]
12. Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouse.
Ritter G; Boosfeld E; Calves MJ; Oettgen HF; Old LJ; Livingston PO
Immunobiology; 1990 Dec; 182(1):32-43. PubMed ID: 2098322
[TBL] [Abstract][Full Text] [Related]
13. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
[TBL] [Abstract][Full Text] [Related]
14. Gonococcal porin vaccine evaluation: comparison of Por proteosomes, liposomes, and blebs isolated from rmp deletion mutants.
Wetzler LM; Blake MS; Barry K; Gotschlich EC
J Infect Dis; 1992 Sep; 166(3):551-5. PubMed ID: 1323620
[TBL] [Abstract][Full Text] [Related]
15. Attachment of monophosphoryl lipid A (MPL) to cells and liposomes augments antibody response to membrane-bound gangliosides.
Ravindranath MH; Morton DL; Irie RF
J Autoimmun; 1994 Dec; 7(6):803-16. PubMed ID: 7888037
[TBL] [Abstract][Full Text] [Related]
16. Very low density lipoproteins and interleukin 2 enhance the immunogenicity of 9-O-acetyl-GD3 ganglioside in BALB/c mice.
Dumontet C; Rebbaa A; Portoukalian J
J Immunol Methods; 1997 Aug; 206(1-2):115-23. PubMed ID: 9328574
[TBL] [Abstract][Full Text] [Related]
17. Preparation of proteosome-based vaccines. Correlation of immunogenicity with physical characteristics.
Ruegg CL; Jaffe RI; Köster B; Sadoff JC; Zollinger WD; Lowell GH; Strand M
J Immunol Methods; 1990 Dec; 135(1-2):101-9. PubMed ID: 2125617
[TBL] [Abstract][Full Text] [Related]
18. Immunization with recombinant truncated Neisseria meningitidis-Macrophage Infectivity Potentiator (rT-Nm-MIP) protein induces murine antibodies that are cross-reactive and bactericidal for Neisseria gonorrhoeae.
Humbert MV; Christodoulides M
Vaccine; 2018 Jun; 36(27):3926-3936. PubMed ID: 29803329
[TBL] [Abstract][Full Text] [Related]
19. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
[TBL] [Abstract][Full Text] [Related]
20. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
Yao TJ; Meyers M; Livingston PO; Houghton AN; Chapman PB
Clin Cancer Res; 1999 Jan; 5(1):77-81. PubMed ID: 9918205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
